Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nidanib to prevent radiation-induced lung injury after radiotherapy in NSCLC
ChiCTR2500100845Phase 4Not yet recruiting
- Sponsor
- Zhangjiakou First Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nintedanib in non-small cell lung cancer (NSCLC) and radiation pneumonitis (RP) (2 arms), sponsored by Zhangjiakou First Hospital. Primary endpoint: Incidence of grade 2 or higher radiation pneumonitis. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)radiation pneumonitis (RP)
Beyond the preview
Go deeper on ChiCTR2500100845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100845.